/
ACAD
$26.65+$0.21 (+0.80%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$4.5B
171M shares
52-week range
$19.69 – $28.35
80% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change+$5.55
Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
www.acadia.com- Employees
- 798
- IPO / List date
- May 27, 2004
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds ACAD.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,724,196 | $38.4M |
| Bridgewater Associatesas of 2026-03-31 | 141,812 | $3.2M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ACAD yet.
